Loading...
•
Jun 30, 2021
McKesson Q1 2022 Earnings Report
McKesson delivered record first-quarter earnings, marking solid performance across all four operating segments. The company evolved its portfolio to drive long-term growth and create shareholder value.
Key Takeaways
McKesson Corporation reported a strong first quarter with total revenues increasing by 13% to $62.7 billion and adjusted earnings per diluted share increasing by 101% to $5.56. The company is raising its fiscal 2022 adjusted EPS guidance based on this performance.
Total revenues increased 13% year-over-year to $62.7 billion.
Earnings per diluted share from continuing operations increased 14% to $3.09.
Adjusted Earnings per diluted share increased 101% to $5.56.
The Board of Directors increased the quarterly dividend by 12% to $0.47 per share.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson raised fiscal 2022 Adjusted Earnings per diluted share guidance to $19.80 to $20.40 from the previous range of $18.85 to $19.45 to reflect strong first-quarter operating performance and increased contribution from the U.S. government's COVID-19 vaccine distribution and kitting programs.
Positive Outlook
- Strong first-quarter operating performance
- Increased contribution from the U.S. government's COVID-19 vaccine distribution programs
- Increased contribution from kitting programs
Challenges Ahead
- Guidance assumes $0.45 to $0.55 related to U.S. government COVID-19 vaccine distribution
- Guidance does not assume any contribution from COVID-19 vaccines designated for pediatric patients or booster shots
- Guidance assumes $0.35 to $0.45 related to the kitting and distribution of ancillary supplies
Revenue & Expenses
Visualization of income flow from segment revenue to net income